These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 9717492)
1. The use of abciximab during percutaneous coronary angioplasty reduces ischaemic events, but the cost is prohibitive. Mayosi BM; Latouf SE; Commerford PJ S Afr Med J; 1998 Feb; 88(2):130-1. PubMed ID: 9717492 [No Abstract] [Full Text] [Related]
2. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Use of abciximab: comparative economic data. Mark DB; Simons TA Am Heart J; 1999 May; 137(5):S123-5. PubMed ID: 10220613 [No Abstract] [Full Text] [Related]
3. [Medico-economic evaluation of abciximab]. Le Pen C; Bonastre J; Pinton P Ann Cardiol Angeiol (Paris); 1999 Jan; 48(1):80-6. PubMed ID: 12555363 [TBL] [Abstract][Full Text] [Related]
4. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. An industry perspective on health economics studies. Anderson KM; Bala MV; Weisman HF Am Heart J; 1999 May; 137(5):S129-32. PubMed ID: 10220615 [No Abstract] [Full Text] [Related]
6. The economics of adjunctive therapies in coronary angioplasty: drugs, devices, or both? Oh PI; Cohen EA; Mittmann N; Seung SJ Can J Clin Pharmacol; 2004; 11(2):e202-11. PubMed ID: 15520474 [TBL] [Abstract][Full Text] [Related]
7. [Abciximab (c7E3)--a new monoclonal antibody--from the pharmaco-economic viewpoint. Initial reports from the literature]. Sturm C Med Klin (Munich); 1996 Nov; 91(11):735-8. PubMed ID: 9036301 [No Abstract] [Full Text] [Related]
8. Should glycoprotein IIb/IIIa inhibitors be used during all percutaneous coronary interventions? Yes. Exaire JE; Lincoff AM J Thromb Haemost; 2004 Jan; 2(1):7-9. PubMed ID: 14717958 [No Abstract] [Full Text] [Related]
9. Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications. van Hout BA; Bowman L; Zelinger DJ; Simoons ML Eur Heart J; 1998 Apr; 19 Suppl D():D59-66. PubMed ID: 9597523 [TBL] [Abstract][Full Text] [Related]
10. Murmurs from the heart (or why the stethoscope is not an economic tool). Aristides M; Gliksman M Heart; 1998 Jan; 79(1):10-1. PubMed ID: 9518073 [No Abstract] [Full Text] [Related]
11. Abciximab. A pharmacoeconomic review of its use in percutaneous coronary revascularisation. Dunn CJ; Foster RH Pharmacoeconomics; 1999 Dec; 16(6):711-41. PubMed ID: 10724797 [TBL] [Abstract][Full Text] [Related]
12. Cost and outcomes analysis of abciximab use in a community teaching hospital. Abernathy GB; Hewitt KK Am J Health Syst Pharm; 1998 Dec; 55(24 Suppl 4):S35-7. PubMed ID: 9872696 [No Abstract] [Full Text] [Related]
13. Are stenting and glycoprotein IIb/IIIa blockade of good value in primary percutaneous coronary intervention? Cole JH; Weintraub WS Circulation; 2003 Dec; 108(23):2831-3. PubMed ID: 14662689 [No Abstract] [Full Text] [Related]
14. Routine use of abciximab in coronary stenting? Stables RH Lancet; 1998 Jul; 352(9122):81-2. PubMed ID: 9672267 [No Abstract] [Full Text] [Related]
15. Difficulties in applying clinical trial information to the practice setting: case of a high-cost drug. Reed SD; Mullins CD; Roffman DS; Mays DA Am J Health Syst Pharm; 1998 Nov; 55(22):2409-14. PubMed ID: 9825038 [No Abstract] [Full Text] [Related]
16. Costs and effects of c7E3 in high risk PTCA patients. An indirect analysis for The Netherlands. van Hout BA; Simoons ML Eur Heart J; 1995 Nov; 16 Suppl L():81-5. PubMed ID: 8869024 [TBL] [Abstract][Full Text] [Related]
18. [An economic assessment of the use of abciximab as a coronary angioplasty preparation in the Italian health-care context]. Lorenzoni R; Mazzotta G; Gensini GF; De Caterina R G Ital Cardiol; 1999 Mar; 29(3):269-76. PubMed ID: 10231672 [TBL] [Abstract][Full Text] [Related]
19. Abciximab therapy in percutaneous intervention: economic issues in the United States. Goklaney AK; Murphy JD; Hillegass WB Am Heart J; 1998 Apr; 135(4):S90-7. PubMed ID: 9539499 [TBL] [Abstract][Full Text] [Related]
20. Effectiveness and cost effectiveness of single bolus treatment with abciximab (Reo Pro) in preventing restenosis following percutaneous transluminal coronary angioplasty in high risk patients. Aristides M; Gliksman M; Rajan N; Davey P Heart; 1998 Jan; 79(1):12-7. PubMed ID: 9505912 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]